Menter, Alan, Andrew Blauvelt, Bruce Strober, Matthew Colombo, Renata Kisa, Sudeep Kundu, Subhashis Banerjee, and Craig Leonardi. “Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis”. SKIN The Journal of Cutaneous Medicine 4, no. 6 (October 27, 2020): s72. Accessed July 22, 2024. https://jofskin.org/index.php/skin/article/view/1105.